Silo Pharma announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury (TBI) and associated neuropsychiatric conditions. The company has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) titled “Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine.”
Clinical Rationale
Silo’s initiative is based on recently published clinical and neuroimaging findings demonstrating substantial improvements in patients with TBI following treatment with ibogaine-based protocols. Reported outcomes include significant reductions in depression and anxiety symptoms, as well as measurable structural brain changes, including increased cortical thickness, subcortical volume expansion, and reductions in predicted brain age following a single treatment.
Ibogaine represents a significant therapeutic opportunity because no FDA-approved treatments currently address the structural or regenerative aspects of traumatic brain injury. Current treatment options are limited to symptomatic support. The global traumatic brain injury therapeutics market is estimated to reach $6.0 billion by 2032, growing at a compound annual growth rate of 6.0% between 2025 and 2032.
FDA Support and Development
In accordance with an Executive Order by President Trump announced on April 18, 2026, the FDA has granted Breakthrough Therapy designation to specific psychedelic drugs through a program designed to expedite the development and review of drugs intended to treat serious or life-threatening conditions. The Executive Order cites ibogaine’s potential for conditions that persist after standard therapies are completed.
Silo CEO Eric Weisblum stated that “while many drugs are used off label to manage TBI symptoms like cognitive dysfunction or depression, no pharmaceutical agent has ever received FDA approval for the direct treatment of TBI.” He noted that “the possibility of not only addressing symptoms but also driving measurable structural brain improvements opens a compelling new frontier in neurotherapeutics.”
Treatment Approach
Silo will evaluate ibogaine and related compounds, including differentiated protocols and combination approaches, as part of its broader strategy to develop next-generation psychedelics-assisted central nervous system therapeutics. The company intends to explore treatment approaches designed to promote neuroplasticity, improve functional outcomes, and address the underlying pathophysiology of TBI. TBI remains a significant unmet medical need, particularly among military veterans and individuals with chronic neuropsychiatric symptoms.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1111081082/Silo-Pharma-Files-Provisional-Patent-For-Ibogaine-Based-Therapeutic-Targeting-Traumatic-Brain-Injury